Return to search results.
Complete title: A Randomized, Phase 2, Open-label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma
|Research Study Number||20110549|
|Principal Investigator||Jonathan Wright|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Bladder Cancer; Genitourinary Cancer; Renal Cancer; Solid Tumors; Urethral Cancer
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.